Schedule 13G ownership disclosure

TRAVERE THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 89422G107

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Rock Springs Capital Management LP

    Shares: 2,921,196.00 · Class: 3.3%

  • Rock Springs Capital LLC

    Shares: 2,921,196.00 · Class: 3.3%

  • Rock Springs Capital Master Fund LP

    Shares: 2,327,521.00 · Class: 2.6%

  • Mark Bussard

    Shares: 2,921,196.00 · Class: 3.3%

  • Kris Jenner

    Shares: 2,921,196.00 · Class: 3.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001172661-25-002075
Form type
SCHEDULE 13G/A
Filer
Rock Springs Capital Management LP
CIK
CIK 1595725
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub